Theranexus announced the initial results of their Phase I/II clinical trial for juvenile Batten disease (CLN3). After a 9-week course of Batten-1 with the maximum dose of 600 mg/day, the first results of the Phase I/II trial enrolling six patients with juvenile Batten disease (CLN3) aged 17 and over showed good patient safety and tolerability, and a pharmacokinetic profile in line with expectations.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.1 EUR | -3.08% | -3.08% | -1.79% |
Apr. 29 | Theranexus Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Apr. 19 | Theranexus: share price rises following promising trial results | CF |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-1.79% | 9.19M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |
- Stock Market
- Equities
- ALTHX Stock
- News Theranexus
- Theranexus Announces the Initial Results of Their Phase I/II Clinical Trial for Juvenile Batten Disease